Ambu (CPH:AMBU-B) announced today that it has secured national single-use endoscopy contract expansions with two major U.S. group purchasing organizations (GPOs).
Ballerup, Denmark–based Ambu is now on contract with all four major GPOs in the U.S. Customers served by the GPOs now have access to either a full or partial portfolio of single-use endoscopy categories.
Ambu’s aScope 4 Cysto has been added to one contract, while Ambu’s aScope Duodeno has been added on another.
“We’re very excited to see that GPOs, with existing contracts, are adding newly released products to expand the dedicated single-use endoscopy categories, serving hospitals and healthcare providers to provide a broader array of advanced single-use devices,” said Steven Block, president of Ambu’s North American business.
“In particular, our duodenoscope contract expansion will accelerate adoption of single-use endoscopy in GI and provide hospitals with additional opportunities to follow the FDA recommendations to transition to new and innovative duodenoscope designs,” Block said.
Duodenoscopes are important medical devices that are used for endoscopic retrograde cholangiopancreatography (ERCP) procedures. However, the devices have had serious problems in the past related to reprocessing. Ambu has been one of the leading companies when it comes to offering single-use innovations.